Zevra Therapeutics Reports Q3 2026 Earnings: Revenue Surges to $37.8 Million, EPS of $0. ...
Revenue of $37.8 Million Edges Past the $37.08 Million Consensus, Aided by Miplyffa Sales and Expanded Access Program Reimbursements Related Stocks: ZVRA ,
Revenue of $37.8 Million Edges Past the $37.08 Million Consensus, Aided by Miplyffa Sales and Expanded Access Program Reimbursements Related Stocks: ZVRA ,